Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0268-0965 · 3 trials · 3 indications
Percent
Number of events
Number of events
| Arm | Type | Description |
|---|---|---|
| NNC0286-0965 | EXPERIMENTAL | NNC0286-0965 administered together with insulin glargine placebo. If previously treated with oral anti-diabetic drugs (OADs), participants will remain on these in the trial |
| Insulin glargine | ACTIVE_COMPARATOR | Insulin glargine administered together with NNC0286-0965 placebo. If previously treated with OADs, participants will remain on these in the trial |
| NNC0268-0965 | EXPERIMENTAL | Participants will receive NNC0268-0965 |
| Part 1 (healthy): NNC0268-0965 | EXPERIMENTAL | A single dose of NNC0268-0965 given s.c. (subcutaneously, under the skin) |
| Part 1 (healthy): placebo | PLACEBO_COMPARATOR | A single dose of placebo (NNC0268-0965) given s.c. |
| Part 2 (type 1 diabetes): NNC0268-0965 | EXPERIMENTAL | A single dose of NNC0268-0965 given s.c. |
| Part 2 (type 1 diabetes): insulin glargine | ACTIVE_COMPARATOR | A single dose of insulin glargine given s.c. |
| Name | Type | Description |
|---|---|---|
| NNC0268-0965 | DRUG | For subcutaneous (s.c., under the skin) injection once daily for 26 weeks |
| Insulin glargine | DRUG | For s.c. injection once daily for 26 weeks |
| Placebo (NNC0268-0965) | DRUG | For s.c. injection once daily for 26 weeks |
| Placebo (insulin glargine) | DRUG | For s.c. injection once daily for 26 weeks |
| Placebo | DRUG | A single dose of placebo given in Part 1 |
Inclusion Criteria: * Informed consent obtained before any trial related activities. Trial related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial. * Aged 40-75 years (both inclusive) at the time of signing informe...
NNC0268-0965 is an investigational small molecule being developed for the treatment of Type 1 and Type 2 diabetes mellitus. It is currently in Phase 1 clinical development and has been studied in healthy volunteers as well as in people with these conditions.
NNC0268-0965 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker symbol NVO. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
NNC0268-0965 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. All completed trials for this drug are Phase 1 studies, and it remains in early-stage clinical testing.
NNC0268-0965 has been studied in three completed Phase 1 clinical trials. These include NCT03965013 in healthy people and people with Type 1 diabetes, NCT04136067 in people with Type 2 diabetes, and NCT04575181 comparing it with insulin glargine in Type 2 diabetes.
No, NNC0268-0965 is not the same as insulin glargine. It is a novel investigational medicine being studied in a clinical trial that compares its efficacy and safety with insulin glargine in people with Type 2 diabetes. The two are distinct treatments.